Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: ethanol; microcrystalline cellulose; purified talc; isopropyl alcohol; dichloromethane; hypromellose phthalate; macrogol 600; butylated hydroxytoluene; povidone; citric acid monohydrate; purified water; hyprolose; tartaric acid; titanium dioxide; macrogol 8000; hypromellose; sunset yellow fcf; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; isopropyl alcohol; dichloromethane; butylated hydroxytoluene; citric acid monohydrate; macrogol 600; purified water; hyprolose; purified talc; hypromellose phthalate; ethanol; tartaric acid; povidone; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; hypromellose; brilliant blue fcf; sunset yellow fcf; allura red ac; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: hyprolose; hypromellose phthalate; butylated hydroxytoluene; purified water; dichloromethane; citric acid monohydrate; macrogol 600; microcrystalline cellulose; tartaric acid; povidone; isopropyl alcohol; ethanol; purified talc; titanium dioxide; macrogol 8000; hypromellose; brilliant blue fcf; sunset yellow fcf; allura red ac; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: citric acid monohydrate; butylated hydroxytoluene; purified talc; ethanol; hypromellose phthalate; povidone; hyprolose; macrogol 600; microcrystalline cellulose; tartaric acid; dichloromethane; purified water; isopropyl alcohol; titanium dioxide; hypromellose; brilliant blue fcf; sunset yellow fcf; allura red ac; macrogol 8000; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 172.95 mg (equivalent: dabigatran etexilate, qty 150 mg) - capsule, hard - excipient ingredients: dichloromethane; isopropyl alcohol; hypromellose phthalate; purified talc; microcrystalline cellulose; ethanol; tartaric acid; citric acid monohydrate; purified water; povidone; hyprolose; macrogol 600; butylated hydroxytoluene; titanium dioxide; macrogol 8000; hypromellose; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; brilliant blue fcf; sunset yellow fcf; allura red ac - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: ethanol; macrogol 600; citric acid monohydrate; butylated hydroxytoluene; tartaric acid; purified water; hyprolose; isopropyl alcohol; dichloromethane; povidone; microcrystalline cellulose; hypromellose phthalate; purified talc; titanium dioxide; hypromellose; brilliant blue fcf; allura red ac; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: dichloromethane; povidone; isopropyl alcohol; tartaric acid; microcrystalline cellulose; ethanol; butylated hydroxytoluene; hyprolose; purified water; macrogol 600; purified talc; citric acid monohydrate; hypromellose phthalate; titanium dioxide; macrogol 8000; hypromellose; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; brilliant blue fcf; allura red ac - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: hypromellose phthalate; microcrystalline cellulose; macrogol 600; ethanol; butylated hydroxytoluene; tartaric acid; povidone; isopropyl alcohol; purified water; dichloromethane; citric acid monohydrate; hyprolose; purified talc; titanium dioxide; hypromellose; brilliant blue fcf; allura red ac; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 126.83 mg (equivalent: dabigatran etexilate, qty 110 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; hyprolose; ethanol; purified water; macrogol 600; povidone; dichloromethane; purified talc; hypromellose phthalate; isopropyl alcohol; tartaric acid; citric acid monohydrate; butylated hydroxytoluene; titanium dioxide; hypromellose; brilliant blue fcf; allura red ac; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; erythrosine; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.